Worldwide revenue increased 36% annually to $11.3 billion in the June quarter, driven mainly by strong sales of Mounjaro, Zepbound, and Verzenio.
Second-quarter reported net income increased 68% from last year to $3.0 billion, or $3.8 per share. Adjusted earnings climbed 86% year-over-year to $3.92 per share.
The management raised its full-year revenue guidance to the range of $45.4 billion to $ 46.6 billion. EPS forecast and adjusted EPS forecast have been raised to $15.10-15.60 and $16.10-16.60, respectively.
ADVERTISEMENT
